U.S. Markets closed
  • S&P 500

    4,109.31
    +58.48 (+1.44%)
     
  • Dow 30

    33,274.15
    +415.12 (+1.26%)
     
  • Nasdaq

    12,221.91
    +208.43 (+1.74%)
     
  • Russell 2000

    1,802.48
    +34.10 (+1.93%)
     
  • Crude Oil

    75.70
    +1.33 (+1.79%)
     
  • Gold

    1,987.00
    -10.70 (-0.54%)
     
  • Silver

    24.24
    +0.25 (+1.03%)
     
  • EUR/USD

    1.0847
    -0.0062 (-0.5640%)
     
  • 10-Yr Bond

    3.4940
    -0.0570 (-1.61%)
     
  • Vix

    18.70
    -0.32 (-1.68%)
     
  • GBP/USD

    1.2332
    -0.0058 (-0.4686%)
     
  • USD/JPY

    132.7970
    +0.1080 (+0.0814%)
     
  • BTC-USD

    28,364.27
    -42.23 (-0.15%)
     
  • CMC Crypto 200

    621.79
    +7.58 (+1.23%)
     
  • FTSE 100

    7,631.74
    +11.31 (+0.15%)
     
  • Nikkei 225

    28,041.48
    +258.55 (+0.93%)
     

Adamis Pharmaceuticals Seeks Strategic Options, Including Sale

  • Adamis Pharmaceuticals Corp (NASDAQ: ADMP) has initiated a process to explore a range of strategic and financing alternatives.

  • The move follows the recently announced halting of the company's Phase 2/3 trial examining the effects of Tempol in high-risk subjects with early COVID-19 infection.

  • In March this year, Adamis voluntarily recalled certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg pre-filled single-dose syringes to the consumer level due to the potential clogging of the needle preventing the dispensing of epinephrine.

  • Potential alternatives that may be explored or evaluated include a partnership or sale of one or both of the company's commercial products, Symjepi and Zimhi, a merger, sale, or reverse merger of the company, and/or seeking additional financing.

  • The company has engaged the investment bank Raymond James & Associates, Inc. as a strategic advisor to assist the company in evaluating options.

  • If the company cannot complete a transaction, it may be required to seek bankruptcy protection or other alternatives for restructuring and resolving its liabilities.

  • ADMP also intends to pursue expense reduction alternatives, including job cuts.

  • Price Action: ADMP shares closed 5.75% higher at $0.17 during after-hours trading on Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.